source
- Novo Nordisk launches Phase 3 trial of lower maintenance doses of oral Wegovy for obesityNovo Nordisk has begun a Phase 3, placebo-controlled study called OASIS 5 to evaluate two lower oral doses of its GLP-1 weight-loss drug Wegovy (semaglutide) in people who are obese or overweight.…
- Replimune appoints former Genentech exec Michelle DiNapoli as chief commercial officer after accelerated melanoma approvalReplimune announced that Michelle DiNapoli will become its chief commercial officer, starting August 18. DiNapoli previously held senior roles at Genentech, where she led commercial operations. Th…